Literature DB >> 8725782

Comparison of the canine and human acid beta-galactosidase gene.

A J Ahern-Rindell1, K A Kretz, J S O'Brien.   

Abstract

Several canine cDNA libraries were screened with human beta-galactosidase cDNA as probe. Seven positive clones were isolated and sequenced yielding a partial (2060 bp) canine beta-galactosidase cDNA with 86% identity to the human beta-galactosidase cDNA. Preliminary analysis of a canine genomic library indicated conservation of exon number and size. Analysis by Northern blotting disclosed a single mRNA of 2.4 kb in fibroblasts and liver from normal dogs and dogs affected with GM1 gangliosidosis. Although incomplete, these results indicate canine GM1 gangliosidosis is a suitable animal model of the human disease and should further efforts to devise a gene therapy strategy for its treatment.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8725782     DOI: 10.1002/(SICI)1096-8628(19960517)63:2<340::AID-AJMG3>3.0.CO;2-X

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  3 in total

1.  Characterization of beta-galactosidase mutations Asp332-->Asn and Arg148-->Ser, and a polymorphism, Ser532-->Gly, in a case of GM1 gangliosidosis.

Authors:  S Zhang; R Bagshaw; W Hilson; Y Oho; A Hinek; J T Clarke; J W Callahan
Journal:  Biochem J       Date:  2000-06-15       Impact factor: 3.857

2.  Isolation and characterization of the normal canine beta-galactosidase gene and its mutation in a dog model of GM1-gangliosidosis.

Authors:  Z H Wang; B Zeng; H Shibuya; G S Johnson; J Alroy; G M Pastores; S Raghavan; E H Kolodny
Journal:  J Inherit Metab Dis       Date:  2000-09       Impact factor: 4.982

3.  Insights into post-translational processing of beta-galactosidase in an animal model resembling late infantile human G-gangliosidosis.

Authors:  R Kreutzer; M Kreutzer; M J Pröpsting; A C Sewell; T Leeb; H Y Naim; W Baumgärtner
Journal:  J Cell Mol Med       Date:  2007-12-14       Impact factor: 5.310

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.